News
More FDA uncertainty roils full approval for Novavax COVID vaccine
Novavax's COVID vaccine was approved under an emergency use authorization in August 2022, and the company has pursued full licensing with the Food and Drug Administration (FDA), which gave the company a decision date of April 1 based on the Prescription Drug User Fee Act.
The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback